在心力衰竭中同情神经系统与保存的射出分数
Joshua W-H Chang1, Rohit Ramchandra2
1Manaaki Manawa - The Centre for Heart Research, Department of Physiology, University of Auckland, Auckland, New Zealand.
Heart failure reviews
|October 22, 2024
概括
尽管有运动不耐受性,但在心力衰竭中,同情神经系统 (SNS) 的活性没有明显升高. 需要进一步的研究,以了解HFpEF患者在炼期间的SNS反应.
科学领域:
- 心血管生理学心血管生理学
- 神经科学是一个神经科学.
- 心脏衰竭研究研究
背景情况:
- 交感神经系统 (SNS) 在健康个体运动期间显著影响心血管功能.
- 运动不耐受是心力衰竭的主要症状,但SNS的作用仍未得到充分研究.
- 现有的关于HFpEF中SNS活动的数据有限,需要进行批判性评估.
研究的目的:
- 审查和分析HFpEF患者对交感神经系统变化的现有数据.
- 突出目前对HFpEF中SNS活动的数据解释的局限性和影响.
- 识别知识缺口,特别是关于在HFpEF中炼过程中的SNS响应.
主要方法:
- 对HFpEF中SNS活动的现有文献进行批判性审查.
- 分析有关肌肉,心脏,脏和脊柱交感神经活动的数据.
- 检查并发症的影响和β-阻断剂疗效的影响.
主要成果:
- 在HFpEF患者中SNS活动的有限直接测量.
- 观察到静止肌肉交感神经活动的适度增加,可能是由于并发症.
- 在HFpEF中没有明确的证据表明心脏,脏或沟交感神经活动升高.
- 贝塔抑制剂缺乏显著的预后益处表明,有限的心交感性过活性.
结论:
- 目前的证据表明,在HFpEF中,交感神经活动的整体升高有限.
- 在HFpEF中观察到的SNS扰动可能不适用于所有患者.
- 在HFpEF中炼过程中SNS的反应仍然是未知的,需要紧急调查.
相关概念视频
01:29Heart Failure II: Pathophysiology
1
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:27Heart Failure I: Introduction
1
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1
01:30Heart Failure V: Medical Management
1
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
1
01:22Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320